Viewing Study NCT06118658

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:03 AM
Ignite Modification Date: 2026-04-13 @ 7:03 PM
Study NCT ID: NCT06118658
Status: NOT_YET_RECRUITING
Last Update Posted: 2023-11-07
First Post: 2023-10-29
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
Sponsor: China Medical University, China
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Gastric View
None Colorectal Adenocarcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None radical resection View
None adjuvant therapy View
None gastric View
None colorectal adenocarcinoma View
None esophagogastric junction adenocarcinoma View
None dMMR/MSI-H or POLE/POLD1 mutations View